300685 Stock Overview
A diagnostic company, focuses on development and commercialization of diagnostics product for oncology in China and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Amoy Diagnostics Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥18.85 |
52 Week High | CN¥25.28 |
52 Week Low | CN¥14.60 |
Beta | 0.67 |
11 Month Change | 0.48% |
3 Month Change | 3.34% |
1 Year Change | -21.62% |
33 Year Change | -52.67% |
5 Year Change | -11.75% |
Change since IPO | 358.97% |
Recent News & Updates
Recent updates
Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?
Aug 23Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's
May 27Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%
Apr 24Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt
Apr 18What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You
Mar 02Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?
Mar 01Shareholder Returns
300685 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 5.7% | 2.3% | 1.5% |
1Y | -21.6% | -22.6% | -18.8% |
Return vs Industry: 300685 matched the CN Biotechs industry which returned -22.6% over the past year.
Return vs Market: 300685 underperformed the CN Market which returned -18.8% over the past year.
Price Volatility
300685 volatility | |
---|---|
300685 Average Weekly Movement | 5.0% |
Biotechs Industry Average Movement | 5.9% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.9% |
10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 300685 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300685's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 1,119 | Jiemin Luo | www.amoydx.com |
Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on development and commercialization of diagnostics product for oncology in China and internationally. It offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions for evaluating PARP inhibitor-related biomarkers and advancing targeted treatment research in ovarian cancer; AmoyDx HRD complete panel to detect genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel that covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel to detect multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel to detect EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. The company also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel to detect single nucleotide variants, insertions, and deletions within pivotal melanoma tumor genes.
Amoy Diagnostics Co., Ltd. Fundamentals Summary
300685 fundamental statistics | |
---|---|
Market cap | CN¥7.44b |
Earnings (TTM) | CN¥278.58m |
Revenue (TTM) | CN¥1.13b |
26.7x
P/E Ratio6.6x
P/S RatioIs 300685 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300685 income statement (TTM) | |
---|---|
Revenue | CN¥1.13b |
Cost of Revenue | CN¥182.74m |
Gross Profit | CN¥945.08m |
Other Expenses | CN¥666.50m |
Earnings | CN¥278.58m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.71 |
Gross Margin | 83.80% |
Net Profit Margin | 24.70% |
Debt/Equity Ratio | 2.9% |
How did 300685 perform over the long term?
See historical performance and comparison